Pricing Log in Create free account
Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.87 1.24 +1.73%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Corcept Therapeutics Incorporated (CORT) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Corcept Therapeutics Incorporated (CORT) trades at a P/B ratio of 9.2×. Over the past ten years it has ranged from 0.0× (March 2015) to 69.0× (June 2015); the current reading is higher than 62% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 5.6× (27.11%)
FY2024 7.7× 55.02%
FY2023 4.9× 15.05%
FY2022 4.3× (29.56%)
FY2021 6.1× 5.62%
FY2020 5.8× 54.77%
FY2019 3.7× (33.27%)
FY2018 5.6× (48.20%)
FY2017 10.8× (45.17%)
FY2016 19.7× (31.66%)

Quarterly newest first

Period P/B ratio Change
Sep 2026 14.7× 13.52%
Jun 2026 13.0× 96.74%
Mar 2026 6.6× 18.26%
Dec 2025 5.6× (59.03%)
43 more quarters

Against its own ten years

Low 0.0× High 69.0×
Ten-year median 6.5×
Current reading's percentile 66

P/B ratio against peers

Company P/B ratio
CYTK Cytokinetics, Incorporated compare n/m
PRAX Praxis Precision Medicines, Inc. compare 5.7×
KRYS Krystal Biotech, Inc. compare 6.2×
CORT Corcept Therapeutics Incorporated 9.2×
SYRE Spyre Therapeutics, Inc. compare 9.5×
PTGX Protagonist Therapeutics, Inc. compare 10.6×
ABVX Abivax SA Sponsored ADR compare 15.8×
ARWR Arrowhead Pharmaceuticals, Inc. compare 17.7×
MDGL Madrigal Pharmaceuticals, Inc. compare 18.7×
Biotechnology industry median 2.0×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on CORT